I-Mab(I-Mab) is a biopharmaceutical company. It develops transformational medicines focused on the therapeutic areas of immuno-oncology and autoimmune diseases. Its pipeline product portfolio comprises TJ202, a CD38 antibody for treating multiple myeloma; TJ101, a recombinant human growth hormone (rhGH) used in pediatric patients with growth hormone deficiency; TJ301, an IL-6 inhibitor for ulcerative colitis; enoblituzumab, a B7-H3 antibody against tumors; and TJ107, an oncology care agent to treat cancer treatment-related lymphopenia. I-Mab utilizes various molecular engineering platforms to develop drug molecules with defined biological properties. The company collaborates with biotechnology companies, CROs, and CMOs to advance the clinical development of its pipeline assets and out-licensing opportunities. It operates in China, Hong Kong, and the US. I-Mab is headquartered in Shanghai, China.
Headquarters
China
Address
Willow House, Floor 4, Shanghai, 200124
Website
www.i-mabbiopharma.com/en
Telephone
86 21 60578000
No of Employees
378
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
IMAB (NASD)
Revenue (2021)
$13.6M
5042.2%
(2021 vs 2020)
EPS
XXX
Net Income (2021)
XXX
132.4%
(2021 vs 2020)
Market Cap*
$949.6M
Net Profit Margin (2020)
XXX
100.6%
(2021 vs 2020)
* As of and is in US$
Explore premium data & analytics
Products and Services
| Products |
|---|
| TJ202: |
| (Felzartamab): Multiple Myeloma |
| TJ101 (eftansomatropin): |
| XXX |
| XXX |
| XXX |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2022 | Contracts/Agreements | In June, the company entered into a strategic collaboration with Ferring Pharmaceuticals to further develop olamkicept in inflammatory bowel disease (IBD) and related inflammatory conditions. |
| 2022 | Official Trials/Tests | In May, the company announced the completion of patient enrollment in a Phase 3 clinical trial to treat pediatric growth hormone deficiency in China. |
| 2022 | Others | In April, the company rating was upgraded by Zacks Investment Research from a sell rating to a hold rating. |
Competitor Comparison
| Key Parameters | I-Mab | CStone Pharmaceuticals Co Ltd | Akeso Inc | JW Cayman Therapeutics Co Ltd | CARsgen Therapeutics Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Shanghai | Shanghai | Zhongshan | Shanghai | Shanghai |
| State/Province | Shanghai | Shanghai | Guangdong | Shanghai | Shanghai |
| No. of Employees | 378 | 263 | 1,865 | 534 | 573 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Operating Margin
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jingwu Zhang Zang | Founder; Chairman; Chief Executive Officer - Acting | Executive Board | 2021 | 66 |
| John Long | Chief Financial Officer; Director | Executive Board | 2021 | 50 |
| Richard Yeh | Director; Chief Operating Officer | Executive Board | 2022 | 54 |
| Andrew Zhu | President; Director | Executive Board | 2021 | 62 |
| Zheru Zhang | Director; President | Executive Board | 2017 | 59 |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer